We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge

The First and Only FDA-approved Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Limitations of Use: REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease
Hypothetical patient and caregiver.
The First and Only FDA-approved Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Limitations of Use: REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease

Hypothetical patient and caregiver.